Articles producció científica> Medicina i Cirurgia

SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)

  • Identification data

    Identifier: imarina:9321032
  • Authors:

    Guma, J
    Palazon-Carrion, N
    Rueda-Dominguez, A
    Sequero, S
    Calvo, V
    Garcia-Arroyo, R
    Gomez-Codina, J
    Llanos, M
    Martinez-Banaclocha, N
    Provencio, M
  • Others:

    Author, as appears in the article.: Guma, J; Palazon-Carrion, N; Rueda-Dominguez, A; Sequero, S; Calvo, V; Garcia-Arroyo, R; Gomez-Codina, J; Llanos, M; Martinez-Banaclocha, N; Provencio, M
    Department: Medicina i Cirurgia
    URV's Author/s: Gumà Padró, José
    Keywords: Treatment Non-hodgkin-lymphoma Guideline Diffuse large b-cell lymphoma Diagnosis treatment single-arm r-chop plus rituximab phase-3 open-label multicenter guideline epoch-r elderly-patients diagnosis chemotherapy
    Abstract: Diffuse large B-cell lymphoma is the most frequent histological subtype of NHL and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hemopathologist is recommended to establish the diagnosis. Twenty years following its introduction, R-CHOP remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significatively improved the clinical outcomes, whereas therapy for recurrence or progression is evolving rapidly. The irruption of CART cells, polatuzumab vedotin, tafasitamab, and CD20/CD3 bispecific antibodies are changing the natural history of relapsed patients and will challenge R-CHOP as the benchmark for newly diagnosed patients.© 2023. The Author(s).
    Thematic Areas: Saúde coletiva Oncology Odontología Medicine (miscellaneous) Medicina veterinaria Medicina ii Medicina i Farmacia Engenharias ii Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: jose.guma@urv.cat
    Author identifier: 0000-0001-7541-9832
    Record's date: 2024-07-20
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://link.springer.com/article/10.1007/s12094-023-03206-5
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Clinical & Translational Oncology. 25 (9): 2749-2758
    APA: Guma, J; Palazon-Carrion, N; Rueda-Dominguez, A; Sequero, S; Calvo, V; Garcia-Arroyo, R; Gomez-Codina, J; Llanos, M; Martinez-Banaclocha, N; Provencio (2023). SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022). Clinical & Translational Oncology, 25(9), 2749-2758. DOI: 10.1007/s12094-023-03206-5
    Article's DOI: 10.1007/s12094-023-03206-5
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2023
    Publication Type: Journal Publications
  • Keywords:

    Cancer Research,Medicine (Miscellaneous),Oncology
    Treatment
    Non-hodgkin-lymphoma
    Guideline
    Diffuse large b-cell lymphoma
    Diagnosis
    treatment
    single-arm
    r-chop
    plus rituximab
    phase-3
    open-label
    multicenter
    guideline
    epoch-r
    elderly-patients
    diagnosis
    chemotherapy
    Saúde coletiva
    Oncology
    Odontología
    Medicine (miscellaneous)
    Medicina veterinaria
    Medicina ii
    Medicina i
    Farmacia
    Engenharias ii
    Ciências biológicas ii
    Ciências biológicas i
    Cancer research
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar